Phase II proof-of-concept study of andexanet alfa with betrixaban in volunteers
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
Price : $35 *
At a glance
- Drugs Andexanet alfa (Primary)
- Indications Haemorrhage
- Focus Pharmacodynamics; Proof of concept
- Sponsors Portola Pharmaceuticals
- 06 Dec 2016 Results of Cohort 1 and 2 (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 07 Nov 2016 According to a Portola Pharmaceuticals media release, data from the study will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting 2016.
- 26 Feb 2016 According to a Portola Pharmaceuticals media release, the company plans to present data from this phase 2 proof-of-concept study of andexanet and betrixaban at a medical conference in 2016.